129 related articles for article (PubMed ID: 34861268)
1. Radiosensitisation of SCCVII tumours and normal tissues in mice by the DNA-dependent protein kinase inhibitor AZD7648.
Hong CR; Buckley CD; Wong WW; Anekal PV; Dickson BD; Bogle G; Hicks KO; Hay MP; Wilson WR
Radiother Oncol; 2022 Jan; 166():162-170. PubMed ID: 34861268
[TBL] [Abstract][Full Text] [Related]
2. Different Impacts of DNA-PK and mTOR Kinase Inhibitors in Combination with Ionizing Radiation on HNSCC and Normal Tissue Cells.
Klieber N; Hildebrand LS; Faulhaber E; Symank J; Häck N; Härtl A; Fietkau R; Distel LV
Cells; 2024 Feb; 13(4):. PubMed ID: 38391917
[TBL] [Abstract][Full Text] [Related]
3. Effective Radiosensitization of HNSCC Cell Lines by DNA-PKcs Inhibitor AZD7648 and PARP Inhibitors Talazoparib and Niraparib.
Mentzel J; Hildebrand LS; Kuhlmann L; Fietkau R; Distel LV
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891817
[TBL] [Abstract][Full Text] [Related]
4. Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia.
Lee TW; Wong WW; Dickson BD; Lipert B; Cheng GJ; Hunter FW; Hay MP; Wilson WR
Int J Radiat Biol; 2019 Dec; 95(12):1597-1612. PubMed ID: 31490091
[No Abstract] [Full Text] [Related]
5. Hypoxia-selective radiosensitisation by SN38023, a bioreductive prodrug of DNA-dependent protein kinase inhibitor IC87361.
Wong WW; Jackson RK; Liew LP; Dickson BD; Cheng GJ; Lipert B; Gu Y; Hunter FW; Wilson WR; Hay MP
Biochem Pharmacol; 2019 Nov; 169():113641. PubMed ID: 31541630
[TBL] [Abstract][Full Text] [Related]
6. AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.
Fok JHL; Ramos-Montoya A; Vazquez-Chantada M; Wijnhoven PWG; Follia V; James N; Farrington PM; Karmokar A; Willis SE; Cairns J; Nikkilä J; Beattie D; Lamont GM; Finlay MRV; Wilson J; Smith A; O'Connor LO; Ling S; Fawell SE; O'Connor MJ; Hollingsworth SJ; Dean E; Goldberg FW; Davies BR; Cadogan EB
Nat Commun; 2019 Nov; 10(1):5065. PubMed ID: 31699977
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control.
Nakamura K; Karmokar A; Farrington PM; James NH; Ramos-Montoya A; Bickerton SJ; Hughes GD; Illidge TM; Cadogan EB; Davies BR; Dovedi SJ; Valge-Archer V
Clin Cancer Res; 2021 Aug; 27(15):4353-4366. PubMed ID: 34011558
[TBL] [Abstract][Full Text] [Related]
8. The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases.
Anastasia A; Dellavedova G; Ramos-Montoya A; James N; Chiorino G; Russo M; Baakza H; Wilson J; Ghilardi C; Cadogan EB; Giavazzi R; Bani MR
Mol Cancer Ther; 2022 Apr; 21(4):555-567. PubMed ID: 35149547
[TBL] [Abstract][Full Text] [Related]
9. Antisense inhibition of ATM gene enhances the radiosensitivity of head and neck squamous cell carcinoma in mice.
Zou J; Qiao X; Ye H; Yang Y; Zheng X; Zhao H; Liu S
J Exp Clin Cancer Res; 2008 Oct; 27(1):56. PubMed ID: 18950535
[TBL] [Abstract][Full Text] [Related]
10. The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-
Goldberg FW; Finlay MRV; Ting AKT; Beattie D; Lamont GM; Fallan C; Wrigley GL; Schimpl M; Howard MR; Williamson B; Vazquez-Chantada M; Barratt DG; Davies BR; Cadogan EB; Ramos-Montoya A; Dean E
J Med Chem; 2020 Apr; 63(7):3461-3471. PubMed ID: 31851518
[TBL] [Abstract][Full Text] [Related]
11. Crizotinib Fails to Enhance the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Xenografts.
Baschnagel AM; Galoforo S; Thibodeau BJ; Ahmed S; Nirmal S; Akervall J; Wilson GD
Anticancer Res; 2015 Nov; 35(11):5973-82. PubMed ID: 26504020
[TBL] [Abstract][Full Text] [Related]
12. Cinnarizine and flunarizine as radiation sensitisers in two murine tumours.
Wood PJ; Hirst DG
Br J Cancer; 1988 Dec; 58(6):742-5. PubMed ID: 3224079
[TBL] [Abstract][Full Text] [Related]
13. CDK4/6 Inhibitor LEE011 Is a Potential Radiation-sensitizer in Head and Neck Squamous Cell Carcinoma: An
Tai TS; Lin PM; Wu CF; Hung SK; Huang CI; Wang CC; Su YC
Anticancer Res; 2019 Feb; 39(2):713-720. PubMed ID: 30711949
[TBL] [Abstract][Full Text] [Related]
14. Bosutinib high density lipoprotein nanoformulation has potent tumour radiosensitisation effects.
Dehghankelishadi P; Badiee P; Maritz MF; Dmochowska N; Thierry B
J Nanobiotechnology; 2023 Mar; 21(1):102. PubMed ID: 36945003
[TBL] [Abstract][Full Text] [Related]
15. Nicotinamide as a radiosensitizer in tumours and normal tissues: the importance of drug dose and timing.
Horsman MR; Siemann DW; Chaplin DJ; Overgaard J
Radiother Oncol; 1997 Nov; 45(2):167-74. PubMed ID: 9424008
[TBL] [Abstract][Full Text] [Related]
16. AZD7648, a DNA-PKcs inhibitor, overcomes radioresistance in Hep3B xenografts and cells under tumor hypoxia.
Ha J; Park M; Lee Y; Choi SH; Kim BS; Ha H; Jeong YK
Am J Cancer Res; 2023; 13(10):4918-4930. PubMed ID: 37970336
[TBL] [Abstract][Full Text] [Related]
17. EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model.
Gustafsson H; Kale A; Dasu A; Lund A; Edqvist PH; Roberg K
Cell Biochem Biophys; 2017 Dec; 75(3-4):299-309. PubMed ID: 28756482
[TBL] [Abstract][Full Text] [Related]
18. Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation.
Yaromina A; Krause M; Thames H; Rosner A; Krause M; Hessel F; Grenman R; Zips D; Baumann M
Radiother Oncol; 2007 Jun; 83(3):304-10. PubMed ID: 17517444
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models.
Zenke FT; Zimmermann A; Sirrenberg C; Dahmen H; Kirkin V; Pehl U; Grombacher T; Wilm C; Fuchss T; Amendt C; Vassilev LT; Blaukat A
Mol Cancer Ther; 2020 May; 19(5):1091-1101. PubMed ID: 32220971
[TBL] [Abstract][Full Text] [Related]
20. Comparison between the comet assay and pimonidazole binding for measuring tumour hypoxia.
Olive PL; Durand RE; Raleigh JA; Luo C; Aquino-Parsons C
Br J Cancer; 2000 Dec; 83(11):1525-31. PubMed ID: 11076663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
